{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:25:52Z","timestamp":1768623952483,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10096-022-04433-4","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T23:02:21Z","timestamp":1647644541000},"page":"849-852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Campylobacter infection in 4 patients treated with ibrutinib"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-9201","authenticated-orcid":false,"given":"Boris","family":"Sorin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehane","family":"Fadlallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Mondesir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Fieschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Galicier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Malphettes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"4433_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133:1298\u20131307. https:\/\/doi.org\/10.1182\/blood-2018-11-846808","journal-title":"Blood"},{"key":"4433_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaip.2018.06.014","volume":"7","author":"J Dion","year":"2019","unstructured":"Dion J, Malphettes M, B\u00e9n\u00e9jat L, M\u00e9graud F, Wargnier A, Boutboul D et al (2019) Campylobacter infection in adult patients with primary antibody deficiency. J Allergy Clin Immunol Pract 7:1038-1041.e4. https:\/\/doi.org\/10.1016\/j.jaip.2018.06.014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4433_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/jcm9020553","volume":"18","author":"I Najjar","year":"2020","unstructured":"Najjar I, Paluca F, Loukidis K, Tarr PE (2020) Recurrent Campylobacter enteritis in patients with hypogammaglobulinemia: review of the literature. J Clin Med 18:9. https:\/\/doi.org\/10.3390\/jcm9020553","journal-title":"J Clin Med"},{"key":"4433_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3181f2638d","volume":"89","author":"A Fern\u00e1ndez-Cruz","year":"2010","unstructured":"Fern\u00e1ndez-Cruz A, Mu\u00f1oz P, Mohedano R, Valerio M, Mar\u00edn M, Alcal\u00e1 L et al (2010) Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore) 89:319\u2013330. https:\/\/doi.org\/10.1097\/MD.0b013e3181f2638d","journal-title":"Medicine (Baltimore)"},{"key":"4433_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10875-020-00830-6","volume":"40","author":"K Inoue","year":"2020","unstructured":"Inoue K, Sasaki S, Yasumi T, Imai K, Kusunoki T, Morio T et al (2020) Helicobacter cinaedi-associated refractory cellulitis in patients with X-linked agammaglobulinemia. J Clin Immunol 40:1132\u20131137. https:\/\/doi.org\/10.1007\/s10875-020-00830-6","journal-title":"J Clin Immunol"},{"key":"4433_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10875-017-0437-z","volume":"37","author":"N Degand","year":"2017","unstructured":"Degand N, Dautremer J, Pilmis B, Ferroni A, Lanternier F, Bruneau J et al (2017) Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia. J Clin Immunol 37:727\u2013731. https:\/\/doi.org\/10.1007\/s10875-017-0437-z","journal-title":"J Clin Immunol"},{"key":"4433_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2169\/internalmedicine.46.6108","volume":"46","author":"A Arai","year":"2007","unstructured":"Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O (2007) Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Intern Med 46:605\u2013609. https:\/\/doi.org\/10.2169\/internalmedicine.46.6108","journal-title":"Intern Med"},{"key":"4433_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/clinids\/23.2.526","volume":"23","author":"IB Autenrieth","year":"1996","unstructured":"Autenrieth IB, Schuster V, Ewald J, Harmsen D, Kreth HW (1996) An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin. Clin Infect Dis 23:526\u2013531. https:\/\/doi.org\/10.1093\/clinids\/23.2.526","journal-title":"Clin Infect Dis"},{"key":"4433_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s10096-019-03499-x","volume":"38","author":"JE Buss","year":"2019","unstructured":"Buss JE, Cresse M, Doyle S, Buchan BW, Craft DW, Young S (2019) Campylobacter culture fails to correctly detect Campylobacter in 30% of positive patient stool specimens compared to non-cultural methods. Eur J Clin Microbiol Infect Dis 38:1087\u20131093. https:\/\/doi.org\/10.1007\/s10096-019-03499-x","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4433_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","volume":"1","author":"SK Fabbro","year":"2015","unstructured":"Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA (2015) Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol 1:684\u2013686. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0457","journal-title":"JAMA Oncol"},{"key":"4433_CR11","doi-asserted-by":"publisher","unstructured":"Singer S, Tan SY, Dewan AK, Davids M, LaCasce AS, Treon SP, et al (2019) Cutaneous eruptions from ibrutinib resembling EGFR inhibitor-induced dermatologic adverse events. J Am Acad Dermatol 20.\u00a0https:\/\/doi.org\/10.1016\/j.jaad.2019.12.031","DOI":"10.1016\/j.jaad.2019.12.031"},{"key":"4433_CR12","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/DAD.0000000000000980","volume":"40","author":"J Stewart","year":"2018","unstructured":"Stewart J, Bayers S, Vandergriff T (2018) Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol 40:e28\u2013e29. https:\/\/doi.org\/10.1097\/DAD.0000000000000980","journal-title":"Am J Dermatopathol"},{"key":"4433_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jdcr.2017.01.027","volume":"3","author":"JA Hammel","year":"2017","unstructured":"Hammel JA, Roth GM, Ferguson N, Fairley JA (2017) Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia. JAAD Case Rep 3:178\u2013179. https:\/\/doi.org\/10.1016\/j.jdcr.2017.01.027","journal-title":"JAAD Case Rep"},{"issue":"373","key":"4433_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"17","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 17(373):2425\u20132437. https:\/\/doi.org\/10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"issue":"369","key":"4433_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"4","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 4(369):32\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1215637","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04433-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:08:08Z","timestamp":1650625688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04433-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was obtained from all the individual participants included in the study to collect and analyze their medical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}